Piedmont Athens Among First Hospitals in U.S. to Implant First-Of-Its-Kind Extravascular Defibrillator to Treat Abnormal Heart Rhythms
Thursday, September 12th, 2024
Kent Nilsson, M.D., and Trent Magruder, M.D., Piedmont Heart Institute physicians who are based at Piedmont Athens Regional, are among the first surgeons in Georgia to successfully implant a novel extravascular defibrillator to treat patients with dangerously fast heart rhythms, a condition that can lead to sudden cardiac arrest (SCA). The Medtronic Extravascular Implantable Cardioverter-Defibrillator (EV-ICD) system, which is composed of the Aurora EV-ICD™ MRI SureScan™, the Epsila EV™ MRI SureScan™ debilitation lead, and proprietary implant tools, received FDA approval in October 2023.
“At Piedmont Athens, we strive to deliver high-quality patient care, and this technology is another step forward in providing our patients with the latest clinical advancements to manage their cardiac condition,” said Dr. Magruder.
The Aurora EV-ICD system is a first-of-its-kind defibrillator with the lead placed under the breastbone, outside of the heart and veins. It delivers lifesaving defibrillation and anti-tachycardia pacing (ATP) therapy all in one system via a single implanted device that is similar in size, shape, and projected longevity to traditional, transvenous ICDs.
“For many years, internal defibrillation devices have been used to restore a normal heartbeat when an arrhythmia is detected by sending an electric pulse to the heart,” explained Dr. Nilsson. “With this new implantable device, we can place a small, battery-powered device below the armpit and the lead under the breastbone, thus significantly reducing the risk of long-term complications associated with leads in the heart and veins.”
The Aurora EV-ICD is implanted below the left armpit, and the Epsila EV defibrillation lead is placed under the breastbone using a minimally invasive approach. Placing the leads outside the heart and veins is designed to help avoid long-term complications that may be associated with transvenous leads, such as vessel occlusion (narrowing, blockage or compression of a vein) and risks for blood infections.
To learn more about cardiovascular services at Piedmont, visit piedmont.org/heart.